Compare Honeywell International Inc (HON) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Recursion Pharmaceuticals Inc — how do they compare? Honeywell International Inc trades at $230.75 (market cap $71.66B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Honeywell International Inc is far larger — about 46.8× Recursion Pharmaceuticals Inc's market cap, and Honeywell International Inc pays a 4.21% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HON | RXRX | |
|---|---|---|
Market Cap | $71.66B | $1.53B |
Sector | Industrials | Health |
52-Week High | $248.04 | $6.79 |
52-Week Low | $188.14 | $2.84 |
Enterprise Value | $96.01B | $946.50M |
Dividend Yield | 4.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $225.78, up 0.34% with a bullish technical signal and strong institutional support. The company maintains solid fundamentals with a 10.89% net margin and 26.41% ROE, though recent earnings show mixed trends with Q1 2026 beating expectations but full-year 2026 guidance indicating potential decline. Recent developments include the completion of a £1.325 billion acquisition and a 2:1 reverse stock split.
The outlook remains positive with analyst consensus favoring Buy ratings (65.52%) and a $368.55 price target representing significant upside. Key risks include execution challenges post-spinoffs and margin pressure, while opportunities lie in automation growth and strategic acquisitions. The stock presents a balanced risk-reward profile for long-term investors.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
